179 related articles for article (PubMed ID: 203543)
21. Specificity of 51Cr-release cytotoxicity of lymphocytes immune to murine sarcoma virus.
Herberman RB; Aoki T; Nunn M; Lavrin DH; Soares N; Gazdar A; Holden H; Chang KS
J Natl Cancer Inst; 1974 Oct; 53(4):1103-11. PubMed ID: 4139276
[No Abstract] [Full Text] [Related]
22. Effect of pretreatment with immune serum on murine sarcoma virus (Moloney) tumour induction and growth.
Guiliani F; Casazza AM; Soranzo C; Di Marco A
Br J Cancer; 1977 Feb; 35(2):190-8. PubMed ID: 189792
[TBL] [Abstract][Full Text] [Related]
23. In vivo interactions between murine leukemia and sarcoma viruses.
Chieco-Bianchi L; Collavo D; Colombatti A; Biasi G
Bibl Haematol; 1975; (40):613-20. PubMed ID: 169829
[TBL] [Abstract][Full Text] [Related]
24. Immunity against Moloney sarcoma virus in H-2Db mutant bm14 mice. Unimpaired tumor immunity despite absence of a virus-specific cytotoxic T-cell response.
Stukart MJ; Boes J; Melief CJ
Int J Cancer; 1984 Feb; 33(2):265-9. PubMed ID: 6319305
[TBL] [Abstract][Full Text] [Related]
25. Immune reactivity in the Moloney strain of murine sarcoma virus oncogenesis: requirement of thymus-derived lymphocytes for in vivo protection.
Collavo D; Colombatti A; Biasi G; Chieco-Bianchi L; Davies AJ
J Natl Cancer Inst; 1976 Mar; 56(3):603-8. PubMed ID: 176399
[TBL] [Abstract][Full Text] [Related]
26. Studies on the susceptibility of C57BL-6 mice to Rauscher virus. 3. Kinetics of humoral antibody response to cell-surface antigens in neonatally inoculated mice.
Ishimoto A; Ito Y
J Natl Cancer Inst; 1973 Aug; 51(2):553-64. PubMed ID: 4765372
[No Abstract] [Full Text] [Related]
27. Induction of effective immunity to Moloney murine sarcoma virus using monoclonal anti-idiotypic antibody as immunogen.
Powell TJ; Spann R; Nguyenduc M; Lamon EW
J Immunol; 1989 Feb; 142(4):1318-24. PubMed ID: 2536772
[TBL] [Abstract][Full Text] [Related]
28. Resistance to Moloney murine sarcoma virus (M-MuSV) tumor induction is associated with natural antibody production to "endogenous" Moloney leukemia virus (M-MuLV) in BALB/Mo mice.
D'Andrea E; De Rossi A; Chieco-Bianchi L
Tumori; 1981 Dec; 67(6):511-20. PubMed ID: 6278685
[TBL] [Abstract][Full Text] [Related]
29. Growth of murine sarcoma and murine xenotropic leukemia viruses in Japanese quail: induction of tumors and development of continuous tumor cell lines.
Robey WG; Kuenzel WJ; Vande Woude GF; Fischinger PJ
Cancer Res; 1982 Jul; 42(7):2523-9. PubMed ID: 6282443
[TBL] [Abstract][Full Text] [Related]
30. [Rejection of non viral tumors caused by infection with murine sarcoma virus].
Basombrio MA
Medicina (B Aires); 1977; 37(2):127-32. PubMed ID: 197370
[No Abstract] [Full Text] [Related]
31. Restriction of Moloney murine leukemia virus replication in Moloney murine sarcoma virus-infected cells.
Yuen PH; Soong MM; Kissil MS; Wong PK
Virology; 1984 Jan; 132(2):377-89. PubMed ID: 6322420
[TBL] [Abstract][Full Text] [Related]
32. Antigenic specificities of the cellular immune response of C57BL/6 mice to the Moloney leukemia/sarcoma virus complex.
Enjuanes L; Lee JC; Ihle JN
J Immunol; 1979 Feb; 122(2):665-74. PubMed ID: 84033
[No Abstract] [Full Text] [Related]
33. In vitro cytotoxicity studies of murine sarcoma virus-induced immunity in mice.
Lavrin DH; Herberman RB; Nunn M; Soares N
J Natl Cancer Inst; 1973 Nov; 51(5):1497-508. PubMed ID: 4762933
[No Abstract] [Full Text] [Related]
34. Suppression of Moloney sarcoma virus immunity following sensitization with attenuated virus.
Wood GW
Cancer Res; 1976 Dec; 36(12):4552-7. PubMed ID: 1000500
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of normal lymphocyte cytotoxicity by sera with high antibody titers against H-2 or virus-associated antigens.
Harada M; Pearson G; Pettigrew H; Redmon L; Orr T
Cancer Res; 1973 Nov; 33(11):2886-93. PubMed ID: 4583975
[No Abstract] [Full Text] [Related]
36. Demonstration of a cell-surface antigen associated with murine sarcoma virus by immunoelectron microscopy.
Aoki T; Stephenson JR; Aaronson SA
Proc Natl Acad Sci U S A; 1973 Mar; 70(3):742-6. PubMed ID: 4351802
[TBL] [Abstract][Full Text] [Related]
37. Anti-tumor immunity in B-lymphocyte-deprived mice. III. Immunity to primary Moloney sarcoma virus-induced tumors.
Gordon J; Holden HT; Segal S; Feldman M
Int J Cancer; 1982 Mar; 29(3):351-7. PubMed ID: 6978293
[TBL] [Abstract][Full Text] [Related]
38. Cell-mediated reaction against tumors induced by oncornaviruses. I. Kinetics and specificity of the immune response in murine sarcoma virus (MSV)-induced tumors and transplanted lymphomas.
Leclerc JC; Gomard E; Levy JP
Int J Cancer; 1972 Nov; 10(3):589-601. PubMed ID: 4128690
[No Abstract] [Full Text] [Related]
39. Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone.
Cerundolo V; Lahaye T; Horvath C; Zanovello P; Collavo D; Engers HD
Eur J Immunol; 1987 Feb; 17(2):173-8. PubMed ID: 3030766
[TBL] [Abstract][Full Text] [Related]
40. Tumor induction by murine sarcoma virus in AKR and C58 mice. Reduction of tumor regression associated with appearance of Gross leukemia virus pseudotypes.
Chieco-Bianchi L; Colombatti A; Collavo D; Sendo F; Aoki T; Fischinger PJ
J Exp Med; 1974 Nov; 140(5):1162-79. PubMed ID: 4608945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
